可调节失禁疗法 (ACT) 治疗女性 SUI
内在括约肌缺陷所致女性压力性尿失禁的可调节尿失禁疗法 (ACT) 的临床研究
A prospective, single arm, non-randomized, multicenter, prospective case-series trial. The purpose of this trial is to demonstrate the safety and effectiveness of using the Adjustable Continence Therapy (ACT) to provide a clinically relevant improvement in stress urinary incontinence.
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Lisa Draper
- 电话号码:612-834-7494
- 邮箱:USLDR@COLOPLAST.COM
研究联系人备份
- 姓名:Matt Kelly, PhD
- 电话号码:612-469-8882
- 邮箱:usmtk@coloplast.com
学习地点
-
-
-
Marseille、法国、13005
- 招聘中
- Hôpital de la Conception - Marseille
-
接触:
- Nassima Rabah
- 电话号码:+33 (0)4 91 38 11 34
- 邮箱:nassima.rabah@ap-hm.fr
-
首席研究员:
- Gilles Karsenty, MD
-
Nantes、法国、44000
- 招聘中
- CHU de Nantes
-
接触:
- Amanda Simon
- 电话号码:+33 2 40 08 39 10
- 邮箱:amanda.simon@chu-nantes.fr
-
首席研究员:
- Marie-Aimee Perrouin-Verbe, MD
-
Paris、法国、75013
- 招聘中
- Pitié Salpêtrière University Hospital Paris
-
接触:
- Kamilia Zedek
- 电话号码:+33 (01) 84 82 83 23
- 邮箱:kamilia.zedek@aphp.fr
-
首席研究员:
- Emmanuel Chartier-Kastler, MD
-
-
-
-
Colorado
-
Denver、Colorado、美国、80045
- 招聘中
- University of Colorado
-
接触:
- Andrea Pina
- 邮箱:andrea.pinalimones@cuanschutz.edu
-
首席研究员:
- Brian Flynn, MD
-
-
Idaho
-
Meridian、Idaho、美国、83642
- 招聘中
- Idaho Urologic Institute, PA
-
接触:
- Karrie Fox
- 邮箱:karried@idurolog.com
-
接触:
- Brian Mihm
- 邮箱:bmihm@idurology.com
-
首席研究员:
- Lisa Parillo, MD
-
-
Missouri
-
Independence、Missouri、美国、64055
- 主动,不招人
- Saint Lukes Health System
-
-
Nebraska
-
Omaha、Nebraska、美国、68124
- 招聘中
- CHI Health Research Center
-
首席研究员:
- Michael Feloney, MD
-
接触:
- Jodi Salvatori, RN, BSN
- 电话号码:402-343-8511
- 邮箱:jodi.salvatori@commonspirit.org
-
-
Pennsylvania
-
Hershey、Pennsylvania、美国、17033
- 招聘中
- Penn State University
-
接触:
- Jocelyn Chavla
- 邮箱:jchavla@pennstatehealth.psu.edu
-
首席研究员:
- Arturo Garcia Mora, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Female at least 22 years old
- Diagnosed with stress urinary incontinence with primary Intrinsic Sphincter Deficiency
- Provocative pad weight of greater than 11.0 grams
- Candidate for surgical intervention
- Negative urinalysis
- Normal cystourethroscopy
- Failed at least 6 months of previous treatment(s) for stress urinary incontinence (e.g., exercise regimen, electrical stimulation, surgical procedures, etc). Note: patients may have failed prior anti-incontinence procedures for SUI (e.g., suspension, sling, or urethral bulking agent)
- Willing and able to sign informed consent and comply with trial follow-up requirements
Exclusion Criteria:
- Pregnant or lactating
- Life expectancy of less than 5 years
- Has uncontrolled diabetes as evidenced by HbA1c over 6.5% and fasting plasma glucose over 130 mg/dL
- Has auto-immune disease
- Undergoing radiation therapy
- Active urinary tract infection
- Detrusor instability refractory to medication
- Reduced bladder compliance as defined by a cystometrogram
- Significant residual volume (greater than 100 ml) after voiding in which detrusor contraction is weak, when the bladder volume is greater than or equal to 250 ml
- Has, had, or is suspected of having bladder cancer
- History of bladder stones
- Urethral stricture evidenced during cystourethroscopy
- Has a neurogenic bladder that is atonic or has detrusor sphincter dyssynergia
- Has a diathesis, hemophilia, or a bleeding disorder
- Has a rectocele, cystocele, urethrocele, enterocele, or pelvic prolapse of grade 3 or higher
- Had prior pelvic radiotherapy
- Had a prior artificial urinary sphincter implanted
- Has a neurogenic condition known to affect bladder/sphincter function
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Adjustable Continence Therapy for Women
Implantation of the Adjustable Continence Therapy for the treatment of female SUI. |
Two ACT devices are implanted in each patient. The devices are intended for implantation in the paraurethral space, with the balloons located on each side of the urethra near the bladder neck. The ports are placed subcutaneously in the labia majora. The balloons are filled after implantation with an isotonic solution via needle injection into the port. The ACT implant can be placed using local, spinal or general anesthesia with the surgical instruments (provided separately). |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Provocative pad weight
大体时间:12 months
|
Change in provocative pad weight from baseline |
12 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Urogenital Distress Inventory (UDI)
大体时间:12 months
|
Six item questionnaire. Scores range from 0-100. 0 being not distressed, 100 being very distressed. |
12 months
|
|
Incontinence Quality of Life Questionnaire (I-QOL)
大体时间:12 months
|
Twenty-two item questionnaire. Scores range from 0-100. 0 being lowest quality of life, 100 being highest quality of life. |
12 months
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Complete adverse event profile
大体时间:12 months
|
Collection of patient safety information |
12 months
|
合作者和调查者
赞助
调查人员
- 研究主任:Philip Johnson, PhD、Uromedica, Inc.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.